AMAG on NASDAQ

AMAG Pharmaceuticals

U.S. pharmaceutical company

AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company was a publicly traded company listed on NASDAQ under the symbol "AMAG" until November 2020 when it was acquired by Covis Pharma. In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).³ It is headquartered in United States.¹ Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Nov 9, 1981Founded¹

Compare with another stock.

TickerAMAG on NASDAQ¹
Industrypharmaceutical industry¹
HeadquartersUnited States¹
Websitewww.amagpharma.com
Legal formDelaware corporation¹
Incorporated inDE⁵
Business address1100 Winter Street, Waltham, Ma 02451⁵
Filer categoryAccelerated filer⁵
LEI549300HCK1560YVVY867⁴
StatusActive⁴
LEI statusLapsed (not renewed)⁴
Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States⁴
Registered withDivision of Corporations, Department of State, 926007⁴

See how the biggest companies compare on our leaderboards

What it owns

What AMAG Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, before depreciation	$15.5M⁷ Dec 31, 2019	$12.7M⁷ Dec 31, 2018	+21.7%
Accumulated depreciation	$11.4M⁷ Dec 31, 2019	$5.2M⁷ Dec 31, 2018	+118.3%
Property and equipment, net	$4.1M⁷ Dec 31, 2019	$7.5M⁷ Dec 31, 2018	−45.3%
Operating-lease assets (leased space)	$23.3M⁷ Dec 31, 2019

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$113.0M⁷ Dec 31, 2019	$253.3M⁷ Dec 31, 2018	−55.4%
Marketable securities, current	$58.7M⁷ Dec 31, 2019	$140.9M⁷ Dec 31, 2018	−58.3%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$422.5M⁷ Dec 31, 2019	$422.5M⁷ Dec 31, 2018	0%
Intangible assets, net (excluding goodwill)	$23.6M⁷ Dec 31, 2019	$217.0M⁷ Dec 31, 2018	−89.1%
Finite-lived intangibles, gross	$953.9M⁸ Dec 31, 2018	$874.8M⁸ Dec 31, 2017	+9.0%
Accumulated amortization	$442.3M⁷ Dec 31, 2019	$417.6M⁷ Dec 31, 2018	+5.9%
Finite-lived intangibles, net	$217.0M⁸ Dec 31, 2018	$296.4M⁸ Dec 31, 2017	−26.8%

Inventory

Item	Latest	A year before	Change
Inventory, total	$31.6M⁷ Dec 31, 2019	$26.7M⁷ Dec 31, 2018	+18.2%
Raw materials	$5.2M⁷ Dec 31, 2019	$9.4M⁷ Dec 31, 2018	−44.5%
Work in process	$6.2M⁷ Dec 31, 2019	$5.9M⁷ Dec 31, 2018	+5.3%
Finished goods	$20.1M⁷ Dec 31, 2019	$11.4M⁷ Dec 31, 2018	+76.7%

Leadership

Who has led AMAG Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive officerScott Dunseth Myers Apr 30, 2020 to Nov 17, 2020⁹
Chief executive officerWilliam K. Heiden May 16, 2012 to Mar 4, 2020¹⁰
Chief executive officerFrank E. Thomas Dec 2, 2011 to Apr 2, 2012¹¹
Chief executive officerJerome Goldstein Jun 8, 2006 to Sep 13, 2006¹²
Chief executive officerBrian Jg Pereira Nov 9, 2006 to Mar 2, 2011¹³
ChairJerome Goldstein Nov 9, 2006 to May 2, 2007¹⁴
PresidentScott Dunseth Myers Apr 30, 2020 to Nov 17, 2020⁹
PresidentFrank E. Thomas Feb 2, 2012 to Feb 27, 2017¹⁵
PresidentWilliam K. Heiden May 16, 2012 to Mar 4, 2020¹⁰
PresidentBrian Jg Pereira Feb 9, 2006 to Mar 2, 2011¹⁶
PresidentJerome Goldstein Jun 8, 2006 to Jun 16, 2006¹²
Chief financial officerBrian Piekos Jun 19, 2020 to Nov 17, 2020¹⁷
Chief financial officerEdward H. Myles Apr 11, 2016 to Mar 12, 2020¹⁸
Chief financial officerEdward C. English Jun 28, 2011 to Jun 28, 2011¹⁹
Chief financial officerFrank E. Thomas Aug 1, 2011 to Jan 4, 2012²⁰
Chief financial officerDavid Arkowitz Apr 5, 2007 to Jun 1, 2011²¹
Chief financial officerMichael N. Avallone Mar 20, 2006 to Feb 6, 2007²²
Chief operating officerEdward H. Myles Feb 25, 2020 to Mar 12, 2020²³
Chief operating officerAnthony Casciano Sep 9, 2020 to Nov 17, 2020²⁴
Chief operating officerFrank E. Thomas Dec 2, 2011 to Feb 27, 2017¹¹

Board members and other officers (45)

Chief Human Resources OfficerKelly Schick Jan 3, 2020 to Nov 17, 2020²⁵
Chief Business Officer, GCJoseph Vittiglio Nov 17, 2020 to Nov 17, 2020²⁶
Chief Commercial OfficerAnthony Casciano Apr 5, 2019 to Apr 6, 2020²⁷
EVP, Chief Business OfficerJames Alan Butcher May 2, 2018 to May 1, 2019²⁸
Chief Human Resources OfficerElizabeth Scott Bolgiano Dec 5, 2017 to May 9, 2019²⁹
Chief Commercial OfficerNicholas Grund Jan 5, 2016 to Mar 5, 2019³⁰
SVP Clinical & Regulatory, CMOJulie Krop Jun 3, 2015 to Mar 4, 2020³¹
EVPGeoffrey Crouse Sep 2, 2015 to Sep 2, 2015³²
SVP, Sales and MarketingP. Jordan Edward Feb 25, 2014 to Mar 5, 2015³³
SVP, Sales and MarketingKenneth H. Wilson Nov 24, 2014 to Dec 4, 2015³⁴
EVP, Chief Commerical OfficerGreg Madison Jan 3, 2013 to Mar 4, 2013³⁵
SVP, Ch. Dev. and Reg. OfficerSteven Caffe Jun 24, 2013 to Aug 21, 2014³⁶
Chief Accounting OfficerScott A. Holmes Dec 20, 2011 to Jun 17, 2015³⁷
EVP, Chief Commercial OfficerGary J. Zieziula Apr 27, 2010 to Jul 29, 2011³⁸
Sr. Vice President, OperationsRicardo Zayas Jun 8, 2009 to Jan 11, 2011³⁹
Senior Vice PresidentLouis Brenner Md. Feb 14, 2007 to Feb 27, 2008⁴⁰
VP of Scientific OperationsJerome M. Lewis Jul 31, 2007 to Aug 7, 2008⁴¹
CMO & SVP Clinical Dev.Lee F. Allen Md. Phd. Aug 6, 2007 to Aug 7, 2012⁴²
Gen Counsel & VP Legal AffairsJoseph L. Farmer May 26, 2006 to Feb 27, 2008⁴³
SVP-Commercial OperationsTimothy G. Healey Dec 1, 2006 to Feb 25, 2010⁴⁴
Board memberScott Dunseth Myers Apr 30, 2020 to Nov 17, 2020⁹
Board memberAnne M. Phillips Apr 12, 2019 to Nov 17, 2020⁴⁵
Board memberKathrine O'Brien Apr 12, 2019 to Nov 17, 2020⁴⁶
Board memberPaul R. Fonteyne Oct 10, 2019 to Nov 17, 2020⁴⁷
Board memberBrian P. Kelley Dec 22, 2016 to May 22, 2017⁴⁸
Board memberJames R. Sulat Apr 16, 2014 to Nov 17, 2020⁴⁹
Board memberBarbara Deptula Sep 9, 2013 to May 20, 2019⁵⁰
Board memberGino Santini Feb 7, 2012 to Nov 17, 2020⁵¹
Board memberSilva Rajiv De Feb 7, 2012 to May 29, 2012⁵²
Board memberWilliam K. Heiden May 16, 2012 to Mar 4, 2020¹⁰
Board memberRobert J. Perez Jan 26, 2009 to May 20, 2019⁵³
Board memberLesley Russell Dec 17, 2009 to Jun 8, 2018⁵⁴
Board memberJoseph Vincent Bonventre Feb 27, 2008 to May 25, 2012⁵⁵
Board memberBrian Jg Pereira Feb 9, 2006 to Mar 2, 2011¹⁶
Board memberMark B. Skaletsky Feb 9, 2006 to Dec 22, 2008⁵⁶
Board memberMichael D. Loberg Feb 9, 2006 to Dec 22, 2008⁵⁷
Board memberSheldon L. Bloch Feb 9, 2006 to Nov 28, 2006⁵⁸
Board memberTheodore I. Steinman Feb 9, 2006 to Nov 9, 2006⁵⁹
Board memberJerome Goldstein Jun 8, 2006 to Sep 13, 2006¹²
Board memberMichael Narachi Nov 9, 2006 to May 24, 2013⁶⁰
Board memberRon Zwanziger Nov 9, 2006 to May 25, 2011⁶¹
Board memberDavey Scoon Dec 1, 2006 to Nov 17, 2020⁶²
General counselJoseph Vittiglio Aug 25, 2015 to Mar 12, 2020⁶³
General counselScott B. Townsend Aug 16, 2012 to Mar 5, 2015⁶⁴
General counselJoseph L. Farmer Feb 18, 2011 to Feb 24, 2012⁶⁵

Products and brands

AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.

AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013.

In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020.

In June 2015, the company acquired Cord Blood Registry for $700 million.

Read the full text

In 2014, AMAG acquired Lumara Health, formerly KV Pharmaceutical Company.

In 2015, the company's revenue reached $418 million. AMAG had 552 employees.

In December 2018, AMAG announced it would acquire Perosphere Pharmaceuticals Inc.

In October 2020, Covis Group agreed to acquire AMAG for $498 million.

From Wikipedia’s article on AMAG Pharmaceuticals, shared under CC BY-SA 4.0.⁶

Former names

AMAG PHARMACEUTICALS INC.Jul 24, 2007 to Jun 28, 2019⁵
ADVANCED MAGNETICS INCMay 10, 1995 to Jul 5, 2007⁵

Timeline

Apr 30, 2020New chief executive Scott Dunseth Myers becomes CEO⁹
May 16, 2012New chief executive William K. Heiden becomes CEO¹⁰
Dec 2, 2011New chief executive Frank E. Thomas becomes CEO¹¹
Nov 9, 2006New chief executive Brian Jg Pereira becomes CEO¹³
Jun 27, 2006Went public Listed on NASDAQ¹
Jun 8, 2006New chief executive Jerome Goldstein becomes CEO¹²
Nov 9, 1981Founded Founded¹

SEC filer profile

How AMAG Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARAMAG PHARMACEUTICALS, INC.²
CIK0000792977
Employer ID (EIN)04-2742593²
Filer statusAccelerated filer²
Incorporated inDelaware²
Fiscal year endsDecember 31²
Industry code (SIC)2834 Pharmaceutical Preparations²
Business address1100 Winter Street, Waltham, MA 02451²
Phone6174983300²
Shares outstanding34,725,063 as of Nov 4, 2020⁶⁶
Public float$335.0M as of Jun 28, 2019⁷
On EDGAR sinceMay 10, 1995²
Filings1,543 in all: 4 (558), 8-K (255), SC 13G/A (158), SC 13G (79), 10-Q (78), 3 (57), CT ORDER (28), DEF 14A (26)²
All 65 form types
UPLOAD (25), 10-K (20), 425 (19), CORRESP (18), S-8 (18), S-8 POS (18), 424B5 (17), SC 13D/A (13), DFAN14A (11), ARS (10), SC 13D (10), 4/A (9), DEFA14A (9), 5 (8), FWP (7), 8-K/A (6), PRE 14A (6), 10-K405 (5), S-3 (5), S-3ASR (5), PREC14A (4), PRER14A (4), PRRN14A (4), EFFECT (3), SC 14D9/A (3), SC TO-T/A (3), SC14D9C (3), 10-K/A (2), 10-Q/A (2), 3/A (2), 305B2 (2), 8-A12B (2), 8-A12B/A (2), DEFC14A (2), POSASR (2), S-3/A (2), S-3MEF (2), SC TO-C (2), 10-K405/A (1), 10-QT (1), 15-12B (1), 25 (1), 25-NSE (1), 424B3 (1), 8-A12G (1), DEFN14A (1), DEFR14A (1), DFRN14A (1), NT 10-Q (1), POS AM (1), PREN14A (1), REGDEX (1), RW (1), S-4 (1), S-4/A (1), SC 14D9 (1), SC TO-T (1)
Latest filingsAnnual report (10-K) Mar 6, 2020
Quarterly report (10-Q) Nov 6, 2020
Proxy statement (DEF 14A) Apr 29, 2020
Latest 8-K (8-K) Nov 17, 2020

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataAMAG Pharmaceuticals on Wikidata
2
SEC EDGARAMAG Pharmaceuticals filings on SEC EDGAR
3
WikipediaAMAG Pharmaceuticals on Wikipedia
4
GLEIFAMAG Pharmaceuticals LEI record (549300HCK1560YVVY867)
5
SEC EDGARAMAG Pharmaceuticals filings on SEC EDGAR
6
WikipediaAMAG Pharmaceuticals on Wikipedia (revision used)
7
SEC EDGARAMAG Pharmaceuticals 10-K/A for fiscal 2019
8
SEC EDGARAMAG Pharmaceuticals 10-K for fiscal 2018
9
SEC EDGARScott Dunseth Myers, Chief executive officer
10
SEC EDGARWilliam K. Heiden, Chief executive officer
11
SEC EDGARFrank E. Thomas, Chief executive officer
12
SEC EDGARJerome Goldstein, Chief executive officer
13
SEC EDGARBrian Jg Pereira, Chief executive officer
14
SEC EDGARJerome Goldstein, Chair
15
SEC EDGARFrank E. Thomas, President
16
SEC EDGARBrian Jg Pereira, President
17
SEC EDGARBrian Piekos, Chief financial officer
18
SEC EDGAREdward H. Myles, Chief financial officer
19
SEC EDGAREdward C. English, Chief financial officer
20
SEC EDGARFrank E. Thomas, Chief financial officer
21
SEC EDGARDavid Arkowitz, Chief financial officer
22
SEC EDGARMichael N. Avallone, Chief financial officer
23
SEC EDGAREdward H. Myles, Chief operating officer
24
SEC EDGARAnthony Casciano, Chief operating officer
25
SEC EDGARKelly Schick, Chief Human Resources Officer
26
SEC EDGARJoseph Vittiglio, Chief Business Officer, GC
27
SEC EDGARAnthony Casciano, Chief Commercial Officer
28
SEC EDGARJames Alan Butcher, EVP, Chief Business Officer
29
SEC EDGARElizabeth Scott Bolgiano, Chief Human Resources Officer
30
SEC EDGARNicholas Grund, Chief Commercial Officer
31
SEC EDGARJulie Krop, SVP Clinical & Regulatory, CMO
32
SEC EDGARGeoffrey Crouse, EVP
33
SEC EDGARP. Jordan Edward, SVP, Sales and Marketing
34
SEC EDGARKenneth H. Wilson, SVP, Sales and Marketing
35
SEC EDGARGreg Madison, EVP, Chief Commerical Officer
36
SEC EDGARSteven Caffe, SVP, Ch. Dev. and Reg. Officer
37
SEC EDGARScott A. Holmes, Chief Accounting Officer
38
SEC EDGARGary J. Zieziula, EVP, Chief Commercial Officer
39
SEC EDGARRicardo Zayas, Sr. Vice President, Operations
40
SEC EDGARLouis Brenner Md., Senior Vice President
41
SEC EDGARJerome M. Lewis, VP of Scientific Operations
42
SEC EDGARLee F. Allen Md. Phd., CMO & SVP Clinical Dev.
43
SEC EDGARJoseph L. Farmer, Gen Counsel & VP Legal Affairs
44
SEC EDGARTimothy G. Healey, SVP-Commercial Operations
45
SEC EDGARAnne M. Phillips, Board member
46
SEC EDGARKathrine O'Brien, Board member
47
SEC EDGARPaul R. Fonteyne, Board member
48
SEC EDGARBrian P. Kelley, Board member
49
SEC EDGARJames R. Sulat, Board member
50
SEC EDGARBarbara Deptula, Board member
51
SEC EDGARGino Santini, Board member
52
SEC EDGARSilva Rajiv De, Board member
53
SEC EDGARRobert J. Perez, Board member
54
SEC EDGARLesley Russell, Board member
55
SEC EDGARJoseph Vincent Bonventre, Board member
56
SEC EDGARMark B. Skaletsky, Board member
57
SEC EDGARMichael D. Loberg, Board member
58
SEC EDGARSheldon L. Bloch, Board member
59
SEC EDGARTheodore I. Steinman, Board member
60
SEC EDGARMichael Narachi, Board member
61
SEC EDGARRon Zwanziger, Board member
62
SEC EDGARDavey Scoon, Board member
63
SEC EDGARJoseph Vittiglio, General counsel
64
SEC EDGARScott B. Townsend, General counsel
65
SEC EDGARJoseph L. Farmer, General counsel
66
SEC EDGARAMAG Pharmaceuticals 10-Q filed Nov 6, 2020: shares outstanding

Overview

What it owns

Property and equipment

Investments

Intangibles and goodwill

Inventory

Leadership

Chief executive

Chair

President

Chief financial officer

Chief operating officer

Products and brands

Former names

Timeline

SEC filer profile

Links

Sources